ImageneBio (NASDAQ:IMA) Cut to “Hold” at Zacks Research

Zacks Research cut shares of ImageneBio (NASDAQ:IMA) from a strong-buy rating to a hold rating in a report released on Monday,Zacks.com reports.

Several other analysts have also recently issued reports on the stock. Wall Street Zen raised shares of ImageneBio to a “hold” rating in a research note on Friday, September 26th. Wedbush decreased their price target on ImageneBio from $25.00 to $23.00 and set a “neutral” rating on the stock in a research note on Friday, July 25th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $35.50.

ImageneBio Price Performance

NASDAQ IMA opened at $8.51 on Monday. The company has a market cap of $34.13 million, a PE ratio of -1.11 and a beta of 0.42. The stock’s 50 day simple moving average is $12.30 and its 200-day simple moving average is $14.07. ImageneBio has a 1-year low of $7.57 and a 1-year high of $23.28.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings results on Thursday, July 24th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.08. On average, equities research analysts anticipate that ImageneBio will post -0.91 EPS for the current fiscal year.

Insider Transactions at ImageneBio

In other ImageneBio news, Director David P. Bonita purchased 83,611 shares of ImageneBio stock in a transaction dated Friday, July 25th. The shares were acquired at an average price of $29.90 per share, with a total value of $2,499,968.90. Following the completion of the transaction, the director owned 287,885 shares of the company’s stock, valued at $8,607,761.50. This trade represents a 40.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Otello Stampacchia acquired 267,556 shares of the stock in a transaction dated Friday, July 25th. The stock was acquired at an average cost of $29.90 per share, with a total value of $7,999,924.40. Following the purchase, the director owned 454,982 shares of the company’s stock, valued at approximately $13,603,961.80. This trade represents a 142.75% increase in their position. The disclosure for this purchase can be found here. 5.94% of the stock is owned by corporate insiders.

Institutional Trading of ImageneBio

A number of large investors have recently modified their holdings of IMA. Squarepoint Ops LLC purchased a new stake in shares of ImageneBio during the fourth quarter worth $72,000. XTX Topco Ltd grew its stake in ImageneBio by 350.6% during the 1st quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock worth $72,000 after purchasing an additional 43,924 shares in the last quarter. Northern Trust Corp increased its holdings in ImageneBio by 19.7% during the 4th quarter. Northern Trust Corp now owns 57,565 shares of the company’s stock worth $94,000 after purchasing an additional 9,456 shares during the period. Goldman Sachs Group Inc. raised its position in ImageneBio by 62.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock valued at $98,000 after purchasing an additional 29,369 shares in the last quarter. Finally, Aldebaran Capital LLC acquired a new stake in ImageneBio in the 1st quarter valued at about $317,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.